Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection.
The antiviral effect (AVE) and interferon neutralizing capacity (INC) of sera originating from either seronegative or HIV-infected individuals were determined. As a rule, sera from seropositive subjects exhibited higher AVE titers than sera from seronegative individuals. Similarly, the INC of sera from HIV-infected patients, was most often stronger than that of sera from seronegative individuals. Furthermore, sera from HIV-infected patients actively immunized with i-IFN alpha invariably expressed INC in response to treatment, which was not the case for sera from control unimmunized patients. All sera from HIV-infected patients were found by ELISA to contain antibodies specifically directed to IFN alpha.
Fall
L S
LS
Laboratoire de Physiologie Cellulaire, Université Pierre et Marie Curie, Paris, France.
Chams
V
V
Le Coq
H
H
Fouchard
M
M
M'Bika
J P
JP
Gringeri
A
A
Santagostino
E
E
Bizzini
B
B
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000821:virology; D000914:Antibodies, Viral / Q000276:immunology*; D000917:Antibody Formation; D000998:Antiviral Agents / Q000097:blood; D018791:CD4 Lymphocyte Count; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000276:immunology*; D016898:Interferon-alpha / Q000097:blood / Q000276:immunology*; D008297:Male; D009500:Neutralization Tests; D013997:Time Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology
D000914:Antibodies, Viral; D000998:Antiviral Agents; D007106:Immune Sera; D016898:Interferon-alpha; D014614:Vaccines, Synthetic